ArticleArchives of microbiology2025
The LuxR family regulator SAV111 enhances avermectin production by binding to aveA1 gene promoter in Streptomyces avermitilis.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Avermectins, macrocyclic lactones produced by Streptomyces avermitilis, serve as essential therapeutic and agrochemical agents. LuxR-type transcriptional regulators are multifunctional proteins known to orchestrate antibiotic biosynthesis alongside virulence modulation, biofilm dynamics, and host immune interactions. However, no prior studies have characterized LuxR-family proteins as direct regulators of avermectin biosynthesis. This study delineates the mechanism through which SAV111, a LuxR-family transcriptional activator, enhances avermectin biosynthesis. Batch fermentation of the SAV111-overexpressing strain demonstrated dual functionality: (1) significant upregulation of avermectin titers and (2) accelerated hyphal growth kinetics. Developmental profiling revealed precocious morphological differentiation in the overexpression strain compared to wild-type controls. Electrophoretic mobility shift assays confirmed direct binding of SAV111 to the aveA1 promoter, encoding the synthase catalytic subunit within the pathway of avermectin biosynthetic. Transcriptional activation of aveA1 represents the primary mechanism underlying SAV111-mediated avermectin overproduction. These findings advance the understanding of LuxR-family regulatory networks in secondary metabolism and establish a molecular framework for engineering hyperproductive S. avermitilis strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.